# SkinBioTherapeutics Plc Files new patent application

- Link: https://www.directorstalkinterviews.com/skinbiotherapeutics-plc-files-new-patent-application/412751009
- Published: 2018-05-14T07:13:32+01:00
- Author: Giles Arbor

**SkinBioTherapeutics plc** (LON:SBTX), a life science company focused on skin health,
announced today a new patent filing.

The patent application is to cover the use of SkinBiotix® for increasing filaggrin
levels in skin.

Filaggrin is a protein which is vital to the formation of the outermost protective
layer of skin. If filaggrin is absent, skin tends to become dry and irritated. It
has been shown that those with severe forms of eczema can have half the level of
filaggrin as a healthy individual. Work performed at the Company’s laboratories 
has demonstrated that SkinBiotix® can significantly increase the amount of filaggrin
in human skin models.

This is the second successful test of the Company’s technology, following earlier
proof that SkinBiotix® increases the ‘tight junction’ which exists in the inner 
layer of skin. The observation that the technology can improve both the surface 
and inner layers of skin suggests that SkinBiotix® will be therapeutically useful
in a range of conditions, such as eczema.

> **Dr Cath O’Neill, CEO of SkinBioTherapeutics Plc, commented:** “SkinBiotix® is
> continuing to prove its uniqueness as a platform via scientific testing. Following
> the successful work in skin models on fillagrin production, we are looking to 
> increase the value and scope of our intellectual property with the filing of this
> patent.
> “This is a continuation of our strategy to create an IP portfolio that allows 
> us to robustly protect what we believe is a technology of significant commercial
> value in key global dermatalogical markets.”

Share on: